Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 15, 2010

Dalton and Lonza Ink Contract Chemistry and Manufacturing Agreement

  • Dalton Pharma Services and Lonza are teaming up to provide their clients with geographically diversified, fully integrated chemistry services from bench to commercial production of APIs. Supplier relationships will be structured to ensure quality and timeliness with a focus on good project management principles and smooth transfers of technology at each critical phase.

    To maximize productivity and capital efficiency, the companies have been seeking partners that can offer the right capabilities at the right stage of the drug development process. "Our clients have been asking for this full spectrum of capabilities to fill an important need in our industry," says Peter Pekos, president and CEO of Dalton Pharma Services. "In Lonza we have the ideal partner: vastly experienced process R&D and scale-up experts with early clinical trial to large-scale commercial cGMP and ISO manufacturing at their sites in Switzerland and China."

    In addition to cGMP manufacturing services, Lonza also offers catalog products and manufacturing services under ISO regulations. Lonza provides contract manufacturing and a complete range of development services for chemicals, advanced intermediates, APIs, biologics, and functional ingredients.

    Dalton supplies cGMP manufacturing of solid dosage forms and aseptic filling services to its customers for all stages of development and commercialization. Dalton can produce APIs at the gram or kilogram scale. It conducts sterile fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized. In addition, Dalton's analytical chemistry laboratory offers method development, validation, and ICH stability programs to its clients.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »